Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
17 evidence topics · 6 sources
Warnings and precautions
Boxed warning: hearing impairment including permanent hearing loss
Hearing impairment: warning and precaution
Hearing impairment with audiometry-guided titration in Trial 3 and the expanded access program
Ataxia: warning and precaution
Fatigue: warning and precaution
Safety population and most common adverse reactions
Common adverse reactions through Week 52 in Trial 1 Parts A and B
| Preferred term | Adrabetadex up to 900 mg (N=32), n (%) | Sham (N=18), n (%) |
|---|---|---|
| Hearing impairment | “23 (71.9)” | “8 (44.4)” |
| Ataxia | “22 (68.8)” | “5 (27.8)” |
| Fatigue | “18 (56.3)” | “5 (27.8)” |
| Vomiting | “17 (53.1)” | “3 (16.7)” |
| Back pain | “16 (50.0)” | “3 (16.7)” |
| Headache | “14 (43.8)” | “3 (16.7)” |
| Pyrexia | “13 (40.6)” | “3 (16.7)” |
| Diarrhea | “10 (31.3)” | “1 (5.6)” |
| Nausea | “8 (25.0)” | “1 (5.6)” |
| Cough | “8 (25.0)” | “4 (22.2)” |
| Contusion | “6 (18.8)” | “2 (11.1)” |
| Pain in extremity | “6 (18.8)” | “1 (5.6)” |
| Epistaxis | “5 (15.6)” | “1 (5.6)” |
| Urinary incontinence | “5 (15.6)” | “1 (5.6)” |
| Muscular weakness | “5 (15.6)” | “0 (0)” |
| Dysarthria | “4 (12.5)” | “1 (5.6)” |
| Skin abrasion | “4 (12.5)” | “1 (5.6)” |
| Nasopharyngitis | “4 (12.5)” | “2 (11.1)” |
Adverse reactions in participants less than 4 years of age
Onset and duration of ataxia and fatigue events
Aspiration pneumonia, including one fatal event after administration with sedation
Overdosage at 1,200 mg and 1,800 mg
Nonclinical carcinogenicity and mutagenicity
Patient counseling on hearing impairment, ataxia, and fatigue
Ototoxicity of 2-hydroxypropyl-beta-cyclodextrin across species: review
“Despite the potential health benefits, use of HPβCD has been linked to significant hearing loss in several species, including humans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ototoxicity can occur following central or peripheral drug delivery, with either route resulting in the preferential loss of cochlear outer hair cells (OHCs) within hours of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The long-term impact of HPβCD use as a maintenance drug, and the mechanism(s) of ototoxicity, are unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet, Kleptose HPB (aka VTS-270) is ototoxic in mice and humans (Davidson et al., 2016; Ory et al., 2017).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, seemingly innocuous doses can become devastating to the ear if administered by different routes close in time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk for functionally significant hearing loss before development of speech and language should be weighed carefully with potential benefits of early-life treatment of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hearing threshold elevation with intracisternal administration in cats
“An increase in hearing threshold was identified as a potential adverse effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our studies in the cat indicate that chronic HPβCD at therapeutic doses is always accompanied by severe hearing loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings have important implications for clinical use in human patients where deafness may be an expected outcome of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events after repeated lumbar puncture for intrathecal delivery at Rush University Medical Center
“Of the 59 patients treated 33 (55.9%) had no adverse events ever after an LP and 26 (44.1%) had adverse effects at some time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 2935 LPs, adverse events occurred after 3.3% of LPs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events most observed were headache (1.2% of LPs), nausea (0.3%), vomiting (1.0%), and back pain (1.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study shows that frequent repeated LPs are possible for delivery of intrathecal therapy and can be accomplished with a very low rate of post-LP adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote